Lisa A de Jong
Overview
Explore the profile of Lisa A de Jong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
50
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Early economic evaluation of chelation therapy in kidney transplant recipients with high-normal lead
Hao J, Alizadeh B, Postma M, Touw D, Bakker S, de Jong L
PLoS One
. 2025 Feb;
20(2):e0319022.
PMID: 40014627
Background: Kidney transplant recipients (KTR) with high-normal lead have a higher risk of graft failure (GF). Clinically, chelation therapy using meso-2,3-dimercaptosuccinic acid (DMSA) removes lead. Despite the proposal that chelation...
2.
de Jong L, Li X, Emamipour S, van der Werf S, Postma M, van Dijk P, et al.
Pharmacoeconomics
. 2024 Jun;
42(9):929-953.
PMID: 38904911
Introduction: This review presents a critical appraisal of differences in the methodologies and quality of model-based and empirical data-based cost-utility studies on continuous glucose monitoring (CGM) in type 1 diabetes...
3.
Bakema R, Smirnova D, Biri D, Kocks J, Postma M, de Jong L
J Med Internet Res
. 2023 Sep;
25:e42474.
PMID: 37751232
Background: eHealth is increasingly considered an important tool for supporting pharmacotherapy management. Objective: We aimed to assess the (1) use of eHealth in pharmacotherapy management with patients with asthma or...
4.
Wolters S, de Jong L, Jansen C, Jansman F, Postma M
Expert Rev Pharmacoecon Outcomes Res
. 2023 Sep;
24(2):251-265.
PMID: 37747280
Objectives: Evidentiary requirements for relative effectiveness assessment vary among European health technology assessment (HTA) bodies, affecting the time to HTA decision-making and potentially delaying time to patient access. Improved alignment...
5.
Paulissen J, Seddik A, Dunton K, Livings C, van Hulst M, Postma M, et al.
Eur J Health Econ
. 2023 Jul;
25(4):689-699.
PMID: 37486557
Objectives: Trastuzumab deruxtecan (T-DXd) was recently recommended by the Committee for Medicinal Products for Human Use as a treatment for adult patients with unresectable or metastatic HER2-positive breast cancer, who...
6.
de Jong L, Groeneveld J, Stevanovic J, Rila H, Tieleman R, Huisman M, et al.
PLoS One
. 2022 Mar;
17(3):e0266625.
PMID: 35358286
[This corrects the article DOI: 10.1371/journal.pone.0222658.].
7.
de Jong L, van der Velden A, van Hulst M, Postma M
BMJ Open
. 2021 Jan;
10(11):e039057.
PMID: 33444193
Objectives: In the 'Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism' (SELECT-D) trial, rivaroxaban showed relatively low venous thromboembolism...
8.
van der Pol S, de Jong L, Vemer P, Jansen D, Postma M
Value Health
. 2020 May;
23(5):675-676.
PMID: 32389235
No abstract available.
9.
van der Pol S, de Jong L, Vemer P, Jansen D, Postma M
Value Health
. 2019 Sep;
22(10):1119-1127.
PMID: 31563254
Background: To assess the cost-effectiveness of new treatments in Germany, the efficiency frontier (EF) method has been developed. We compared the cost-effectiveness analysis using international standards and the German methodology,...
10.
Gout-Zwart J, de Jong L, Saptenno L, Postma M
Pharmacoecon Open
. 2019 Sep;
4(2):321-330.
PMID: 31535305
Background: Adverse drug reactions and medication nonadherence are well-known causes of sub-optimal disease control and worsened disease outcomes in patients who are treated for type 2 diabetes. Metformin sustained release...